Should we resurface the patella in total knee replacement?

Patellar resurfacing is a controversial issue in primary total knee replacement. So, we took advantage of a large study to try and answer this question. An open prospective multicentric study was conducted about the outcome of the Nex Gen Total Knee prosthesis with clinical and radiological follow-up at regular intervals (1, 2 and 5 years). The data were centrally collected and analyzed by independent observers. A total of whole 5,915 cases were included (487 in the French group); incidences of patello-femoral pain were observed in both French and international groups and compared between cases with or without resurfaced patellae. Only osteoarthritic cases were selected for this particular study. Statistical analysis was performed using a Pearsons Chi-square test with a 95% confidence interval. The frequency of preoperative pain was significantly higher in the French group; 85.1% versus 66.6% (p<0.05). No patello-femoral pain appeared in preoperatively painless patients in the French group. The frequency of lateral patellar release was similar in both groups. 35.7% of the patellae were resurfaced in the international group versus 98.8% in the French one. At 2 years, patello-femoral pain was observed in 6.3% of cases in the former group versus 0.7% in the latter one. The risk of having patello-femoral pain was 9.45 times higher in the international group. When considering resurfaced cases in both groups the risk of having anterior knee pain was not significantly different (p=0.35). In the French group, one case out of nine (11.1%) with patello-femoral pain had not been resurfaced, while 129 cases out of 151 (85.4%) had not had a resurfacing in the international group. This emphasizes the effect of patellar implant on pain. Although patello-femoral pain is multifactorial, this analysis tool is powerful in getting rid of the center effect (cf Swedish register). Even if a longer follow-up for confirmation is needed, our data favor patellar resurfacing with this type of implant in spite of the fact that the trochlear design was considered as anatomical.     

Nitinol Stents for Palliative Treatment of Malignant Obstructive Jaundice: Should We Stent the Sphincter of Oddi in Every Case?

Purpose: To evaluate the necessity of metallic stenting of the sphincter of Oddi in malignant obstructive jaundice when the tumor is more than 2 cm from the papilla of Vater. Methods: Sixty-seven self-expandable biliary stents were used in 60 patients with extrahepatic lesions of the common hepatic or common bile duct and with the distal margin of the tumor located more than 2 cm from the papilla of Vater. Stents were placed above the papilla in 30 cases (group A) and in another 30 with their distal part protruding into the duodenum (group B). Results: The 30-day mortality was 15%, due to the underlying disease. The stent occlusion rate was 17% after a mean period of 4.3 months. No major complications were noted. Average survival was 132 days for group A and 140 days for group B. In group A, 19 patients survived ≤ 90 days and in eight of these, cholangitis occurred at least once. Of 11 patients in group A with survival > 90 days, only two developed cholangitis. In group B, 13 patients who survived ≤ 90 days had no episodes of cholangitis and in 17 with survival > 90 days, cholangitis occurred in three. There is a statistically significant difference (p < 0.05) regarding the incidence of cholangitis in favor of group A. Conclusions: In patients with extrahepatic lesions more than 2 cm from the papilla and with a relative poor prognosis (≤ 3 months), due to more advanced disease or to a worse general condition, the sphincter of Oddi should also be stented in order to reduce the postprocedural morbidity.     

Should We Screen Oncotype DX Eligible Patients With Breast MRI?

PurposeOncotype DX is a genomic test used to predict chemotherapy benefit and recurrence risk in early stage breast cancer patients. A previous study has shown that in patients with multiple tumors sent for Oncotype DX analysis, differing results between the tumors were yielded that ultimately changed chemotherapy management in 27% of cases. The purpose of this study is to determine the utility of preoperative MRI in Oncotype DX eligible patients.MethodsA retrospective, Institutional review board approved study identified 888 consecutive new breast cancer patients from 2012 to 2016 at a single institution and identified 541 patients who potentially would be eligible for Oncotype DX. Frequency of additional disease in this population group was recorded. The method of imaging used, either conventional imaging (mammography and ultrasound) or additional MRI, was evaluated.ResultsOf 541 patients, 360 patients had conventional imaging performed only and 181 patients had an additional breast MRI. Of 541 patients, 73 patients (13.5%) had additional biopsy proven multifocal, multicentric, or contralateral tumors identified. The total number of additional disease within the conventional imaging group was 39 of 360 patients (10.8%), vs 34 of 181 patients (18.8%) in the MRI group, which was statistically significant (P = 0.02). Total 34 of 73 patients (46.6%) had additional disease only detected by MRI.ConclusionsIn patients who may be eligible for Oncotype DX evaluation, 13.5% of patients were found to have additional disease. Nearly half of the patients had additional disease only detected by MRI, indicating the potentially utility of preoperative MRI in this patient population.     

Pelvic Congestion Syndrome,Who Should We Treat and How?

Pelvic congestion syndrome (PCS) is a condition that is difficult to diagnose but causes distress to a significant number of women. It is not difficult to treat by embolization but the technique is still evolving and results are by no means perfect. Nevertheless, the results of endovascular treatment are at least equivalent to those of surgery and better than conventional medical therapy. This paper will review the techniques and results reported for treatment of pelvic congestion syndrome.     

Endovascular Stroke Treatment: How Far Downstream Should We Go?

CardioVascular and Interventional Radiology - Endovascular thrombectomy has become the de facto standard in the treatment of large vessel occlusion. Previously, a correlation between good outcome...     

Should previous mammograms be digitised in the transition to digital mammography?

Breast screening specificity is improved if previous mammograms are available, which presents a challenge when converting to digital mammography. Two display options were investigated: mounting previous film mammograms on a multiviewer adjacent to the workstation, or digitising them for soft copy display. Eight qualified screen readers were videotaped undertaking routine screen reading for two 45-min sessions in each scenario. Analysis of gross eye and head movements showed that when digitised, previous mammograms were examined a greater number of times per case (p = 0.03), due to a combination of being used in 19% more cases (p = 0.04) and where used, looked at a greater number of times (28% increase, p = 0.04). Digitising previous mammograms reduced both the average time taken per case by 18% (p = 0.04) and the participants’ perceptions of workload (p < 0.05). Digitising previous analogue mammograms may be advantageous, in particular in increasing their level of use.     

Long-Term Retrievability of IVC Filters: Should We Abandon Permanent Devices?

Thromboembolic disease produces a considerable disease burden, with death from pulmonary embolism in the UK alone estimated at 30,000–40,000 per year. Whilst it is unproven whether filters actually improve longevity, the morbidity and mortality associated with thromboembolic disease in the presence of contraindications to anticoagulation is high. Thus complications associated with filter insertion, and whilst they remain in situ, must be balanced against the alternatives. Permanent filters remain in situ for the remainder of the patient’s life and any complications from the filters are of significant concern. Filters that are not permanent are therefore attractive in these circumstances. Retrievable filters, to avoid or decrease long-term filter complications, appear to be a significant advance in the prevention of pulmonary embolism. In this review, we discuss the safety and effectiveness of both permanent and retrievable filters as well as the retrievability of retrievable inferior vena cava (IVC) filters, to explore whether the use of permanent IVC filters can be abandoned in favor of retrievable filters. Currently four types of retrievable filters are available: the Recovery filter (Bard Peripheral Vascular, Tempe, AZ, USA), the Günther Tulip filter (Cook, Bloomington, IN, USA), the OptEase Filter (Cordis, Roden, The Netherlands), and the ALN filter (ALN Implants Chirurgicaux, Ghisonaccia, France). Efficacy and safety data for retrievable filters are as yet based on small series, with a total number of fewer than 1,000 insertions, and follow-up is mostly short term. Current long-term data are poor and insufficient to warrant the long-term implantation of these devices into humans. The case of fractured wire from a Recovery filter that migrated to the heart causing pericardial tamponade requiring open heart surgery is a reminder that any new endovascular device remaining in situ in the long term may produce unexpected problems. We should also bear in mind that the data on permanent filters are much more robust, with reports on over 9,500 cases with follow-up of up to 8 years. The original implantation time of 10–14 days has been extended to more than 100 days as the mean implantation time with some of the filter types. Follow-up (preferably prospective) is necessary for all retrievable filters, whether or not they are retrieved. Until these data become available we should restrict ourselves to the present indications of permanent and retrievable filters. If long-term follow-up data on larger numbers of cases confirm the initial data that retrievable filters are as safe and effective as permanent filters, the use of the retrievable filters is likely to expand. V. Berczi and J. Bottomley have contributed equally to this paper.